A carregar...
32 doses of bortezomib for desensitization is not well-tolerated and is associated with only modest reductions in anti-HLA antibody
BACKGROUND: We previously showed that bortezomib (BTZ) partially depletes plasma cells, yet has limited efficacy for desensitization in kidney transplant (KTx) candidates when up to 16 doses is given. METHODS: This study aimed to determine the safety and efficacy of 32 doses of BTZ (1.3mg/m(2) of bo...
Na minha lista:
| Publicado no: | Transplantation |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4935916/ https://ncbi.nlm.nih.gov/pubmed/27379560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0000000000001330 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|